# Adam D. Cohen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/adam-d-cohen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,952 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 65 |
| i10-index | 169 |
| Last Known Institution | Penn Center for AIDS Research |
| OpenAlex ID | https://openalex.org/A5025168585 |
| ORCID iD | https://orcid.org/0000-0003-0939-3843 |
| Works | 439 |

## Researcher papers

- [Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study](https://scholariq.org/papers/ciltacabtagene-autoleucel-a-b-cell-maturation-antigen-directed-chimeric-antigen/)
- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma](https://scholariq.org/papers/b-cell-maturation-antigen-specific-car-t-cells-are-clinically-active-in-multiple/)
- [Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma](https://scholariq.org/papers/chimeric-antigen-receptor-t-cells-against-cd19-for-multiple-myeloma/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial](https://scholariq.org/papers/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)

## Researcher university

- [Penn Center for AIDS Research](https://scholariq.org/institutions/penn-center-for-aids-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.